

APPLICANTS: Vickers et al.  
SERIAL NO: 10/664,639

DOCKET NO: CORE0027US

**AMENDMENTS TO THE CLAIMS:** This listing of claims replaces all prior versions and listings of claims in the instant patent application.

**Listing of claims:**

- 1-84. (Canceled)
85. (Previously presented) A method of eliciting cleavage of a target mRNA in a cell, comprising contacting said cell with an antisense oligoribonucleotide 12 to 30 nucleobases in length targeted to said RNA, wherein said oligoribonucleotide comprises (i) no more than two mismatched nucleobases relative to said RNA and (ii) three 2'-O-methyl modifications on the 3' terminus.
86. (Previously presented) The method of claim 85 wherein said oligoribonucleotide further comprises a 5' terminal phosphate.
87. (Previously presented) The method of claim 85 wherein said oligoribonucleotide further comprises at least one phosphorothioate internucleoside linkage.
88. (Previously presented) The method of claim 87 wherein said oligoribonucleotide comprises a phosphorothioate internucleoside linkage at each position.
89. (Previously presented) The method of claim 85 wherein said oligoribonucleotide is 100% complementary to said RNA.
90. (Previously presented) A method of eliciting cleavage of a target RNA in a cell, comprising contacting said cell with an antisense oligoribonucleotide 12 to 30 nucleobases in length targeted to said RNA, wherein said oligoribonucleotide comprises (i) no more than two mismatched nucleobases relative to said target mRNA and (ii) 2'-fluoro modifications throughout the oligoribonucleotide.
91. (Previously presented) The method of claim 90 wherein said oligoribonucleotide further comprises a 5' terminal phosphate.
92. (Previously presented) The method of claim 90 wherein said oligoribonucleotide further comprises at least one phosphorothioate internucleoside linkage.
93. (Previously presented) The method of claim 92 wherein said oligoribonucleotide comprises a phosphorothioate internucleoside linkage at each position.

**APPLICANTS: Vickers et al.**  
**SERIAL NO: 10/664,639**

**DOCKET NO: CORE0027US**

94. (Previously presented) The method of claim 90 wherein said oligoribonucleotide is 100% complementary to said RNA.

95. (Previously presented) A method of eliciting cleavage of a target RNA in a cell, comprising contacting said cell with an antisense oligoribonucleotide 12 to 30 nucleobases in length targeted to said RNA, wherein said oligoribonucleotide comprises (i) no more than two mismatched nucleobases relative to said target mRNA and (ii) three to seven 2' modifications on the 3' terminus.

96. (Previously presented) The method of claim 95 wherein said oligoribonucleotide further comprises a 5' terminal phosphate.

97. (Previously presented) The method of claim 95 wherein said oligoribonucleotide further comprises at least one phosphorothioate internucleoside linkage.

98. (Previously presented) The method of claim 97 wherein said oligoribonucleotide comprises a phosphorothioate internucleoside linkage at each position.

99. (Previously presented) The method of claim 95 wherein said oligoribonucleotide is 100% complementary to said RNA.

100-107. (Canceled)